{"pmid":32445400,"title":"Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?","text":["Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?","J Clin Pharmacol","Nasiripour, Somayyeh","Zamani, Farhad","Farasatinasab, Maryam","32445400"],"journal":"J Clin Pharmacol","authors":["Nasiripour, Somayyeh","Zamani, Farhad","Farasatinasab, Maryam"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445400","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jcph.1645","keywords":["covid-19","colchicine"],"locations":["Colchicine"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1667600475782905857,"score":9.490897,"similar":[{"pmid":32492478,"pmcid":"PMC7261351","title":"Treating COVID-19 with colchicine in community healthcare setting.","text":["Treating COVID-19 with colchicine in community healthcare setting.","Clin Immunol","Della-Torre, Emanuel","Della-Torre, Fabrizio","Kusanovic, Marija","Scotti, Raffaella","Ramirez, Giuseppe-Alvise","Dagna, Lorenzo","Tresoldi, Moreno","32492478"],"journal":"Clin Immunol","authors":["Della-Torre, Emanuel","Della-Torre, Fabrizio","Kusanovic, Marija","Scotti, Raffaella","Ramirez, Giuseppe-Alvise","Dagna, Lorenzo","Tresoldi, Moreno"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492478","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.clim.2020.108490","keywords":["covid-19","colchicine","community","inflammation","sars-cov-2"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1668892169408086016,"score":80.044815},{"pmid":32426001,"pmcid":"PMC7229928","title":"[Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients].","text":["[Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients].","COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnoea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article.","Reumatol Clin","Montealegre-Gomez, Giovanni","Garavito, Edgar","Gomez-Lopez, Arley","Rojas-Villarraga, Adriana","Parra-Medina, Rafael","32426001"],"abstract":["COVID-19 is a newly emerged disease that has become a global public health challenge. Due to a lack of knowledge about the virus, a significant number of potential targets for using a particular drug have been proposed. Five cases with a clinical history of biopolymers in the gluteal region that developed iatrogenic allogenosis (IA) are presented here. The 5 cases were put under colchicine treatment for IA crisis and had non-specific symptoms (headache, cough without dyspnoea, and arthralgias) with a positive SARS-CoV-2 test. Their close contacts had mild to severe symptoms and three of them died. In the SARS-CoV-2 infection different inflammatory pathways are altered where colchicine reduces cytokine levels as well as the activation of macrophages, neutrophils, and the inflammasome. The possible mechanisms that colchicine may use to prevent acute respiratory distress syndrome (ARDS) in patients with COVID-19 infection are also reviewed in this article."],"journal":"Reumatol Clin","authors":["Montealegre-Gomez, Giovanni","Garavito, Edgar","Gomez-Lopez, Arley","Rojas-Villarraga, Adriana","Parra-Medina, Rafael"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426001","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.reuma.2020.05.001","keywords":["ards","covid-19","colchicine","inflammasome","sars-cov-2"],"locations":["Colchicine"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1667352728732434432,"score":78.451324},{"pmid":32337546,"pmcid":"PMC7197570","title":"Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?","text":["Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?","Eur Heart J Cardiovasc Pharmacother","Deftereos, Spyridon","Giannopoulos, George","Vrachatis, Dimitrios A","Siasos, Gerasimos","Giotaki, Sotiria G","Cleman, Michael","Dangas, George","Stefanadis, Christodoulos","32337546"],"journal":"Eur Heart J Cardiovasc Pharmacother","authors":["Deftereos, Spyridon","Giannopoulos, George","Vrachatis, Dimitrios A","Siasos, Gerasimos","Giotaki, Sotiria G","Cleman, Michael","Dangas, George","Stefanadis, Christodoulos"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32337546","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1093/ehjcvp/pvaa033","locations":["Colchicine"],"e_drugs":["Colchicine"],"topics":["Treatment"],"weight":1,"_version_":1666138494258380800,"score":76.17187},{"pmid":32472681,"title":"Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.","text":["Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.","Rheumatology (Oxford)","Piantoni, Silvia","Patroni, Andrea","Toniati, Paola","Furloni, Roberto","Franceschini, Franco","Andreoli, Laura","Scarsi, Mirko","32472681"],"journal":"Rheumatology (Oxford)","authors":["Piantoni, Silvia","Patroni, Andrea","Toniati, Paola","Furloni, Roberto","Franceschini, Franco","Andreoli, Laura","Scarsi, Mirko"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472681","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1093/rheumatology/keaa217","topics":["Treatment"],"weight":1,"_version_":1668255193465094145,"score":74.91276},{"pmid":32380315,"pmcid":"PMC7198406","title":"Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.","text":["Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.","BACKGROUND: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the \"coronavirus disease 2019\" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. METHODS: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the \"Severe Acute Respiratory Syndrome Coronavirus type 2\" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy. RESULTS: An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). CONCLUSION: These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.","Autoimmun Rev","Gendelman, Omer","Amital, Howard","Bragazzi, Nicola Luigi","Watad, Abdulla","Chodick, Gabriel","32380315"],"abstract":["BACKGROUND: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the \"coronavirus disease 2019\" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. METHODS: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the \"Severe Acute Respiratory Syndrome Coronavirus type 2\" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/colchicine therapy. RESULTS: An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). CONCLUSION: These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection."],"journal":"Autoimmun Rev","authors":["Gendelman, Omer","Amital, Howard","Bragazzi, Nicola Luigi","Watad, Abdulla","Chodick, Gabriel"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32380315","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102566","keywords":["autoimmunity","covid-19","colchicine","hydroxychloroquine","rheumatic disease","sars-cov-2"],"e_drugs":["Colchicine","Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666597097430843392,"score":71.52366}]}